The main protease of SARS-CoV-2 (MPro) plays a key role in viral replication, as it is essential for the processing of viral polyproteins. Its enzymatic activity depends on the formation of a homodimer, which provides an opportunity for alternative therapeutic strategies based on inhibiting dimerization rather than directly targeting the catalytic site of the enzyme.
The aim of this master’s thesis was to prepare a library of different affibody variants and to identify an affibody capable of disrupting the homodimerization of the MPro protease. The ability to interfere with dimerization was assessed using a bacterial Escherichia coli system designed for the detection of protein homodimerization. For this purpose, the previously established LexGFP system was modified to generate the LexKan system, in which disruption of homodimerization results in the expression of kanamycin resistance. This setup allows for the selection of bacterial cells in which MPro dimerization has been disrupted by the tested affibodies.
Appropriate plasmid constructs were prepared using Gibson cloning, and an improved LexKan system for monitoring homodimerization was successfully established. The pAFI plasmid, containing the affibody sequence and a chloramphenicol resistance marker, was constructed through two consecutive Gibson cloning steps. This plasmid was used as a template for the generation of an affibody library using degenerate megaprimers, introducing random mutations at selected amino acid positions on the binding surface. Library selection was subsequently performed using the LexKan system.
The results showed that the LexKan system is suitable for detecting homodimerization of protein targets in a bacterial environment, as demonstrated by the appropriate negative control. Although no affibody capable of efficiently disrupting MPro dimerization was identified within the scope of this work, the study demonstrates that the generation of an affibody library using degenerate megaprimers is feasible. In addition, several aspects of the system were identified that could be optimized to improve future selection efficiency. The LexKan system, which is based on chimeric LexA transcription factors, therefore represents a promising tool for studying protein–protein interactions and may be applicable to the development of therapeutic strategies targeting protein dimerization.
|